US OptionsDetailed Quotes
AUTL241220P5000
- 2.00
- 0.000.00%
15min DelayClose Nov 29 13:00 ET
0.00High0.00Low
2.00Open2.00Pre Close0 Volume57 Open Interest5.00Strike Price0.00Turnover255.45%IV9.64%PremiumDec 20, 2024Expiry Date1.68Intrinsic Value100Multiplier19DDays to Expiry0.32Extrinsic Value100Contract SizeAmericanOptions Type-0.6595Delta0.1906Gamma1.66Leverage Ratio-0.0184Theta-0.0018Rho-1.09Eff Leverage0.0028Vega
Autolus Therapeutics Stock Discussion
ya I'm getting in here
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
• AUCATZYL is the first CAR T therapy approved by the FDA with no requirement for a REMS program (Risk Evaluation Mitigation Strategy)
• Approval based on FELIX clinical trial of obe-cel in adult patients with r/r B-ALL
• Conference call to be held on November 11 at 08:30 am EST/13:3...
Abeona Therapeutics ( $Abeona Therapeutics (ABEO.US)$ )
Asset: Pz-cel (prademagene zamikeracel)
PDUFA Date: May 25, 2024
Indication: Recessive dystrophic epidermolysis bullosa (RDEB)
Technology: Autologous cell therapy, treatment uses gene transfer to deliver COL7A1 genes into an RDEB patient’s own skin cells then transplanting them back to the patient.
Rocket Pharmaceuticals ( $Rocket Pharmaceuticals (RCKT.US)$ ) ...
No comment yet